Syndax Pharmaceuticals (SNDX)
(Delayed Data from NSDQ)
$23.80 USD
+0.73 (3.16%)
Updated Mar 28, 2024 03:59 PM ET
After-Market: $23.78 -0.02 (-0.08%) 5:24 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Syndax Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 578 | 484 | 440 | 293 | 60 |
Receivables | 0 | 3 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 2 | 8 | 6 | 3 |
Total Current Assets | 581 | 490 | 448 | 299 | 62 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 30 | 5 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 0 | 1 | 0 |
Total Assets | 613 | 497 | 450 | 301 | 64 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 4 | 6 | 4 | 6 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 2 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 40 | 24 | 14 | 11 | 10 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 0 | 0 | 2 | 2 |
Total Current Liabilities | 58 | 29 | 21 | 19 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 12 | 13 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 20 | 18 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 59 | 30 | 41 | 48 | 32 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,456 | 1,161 | 952 | 821 | 527 |
Retained Earnings | -902 | -693 | -544 | -569 | -495 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 554 | 467 | 408 | 252 | 32 |
Total Liabilities & Shareholder's Equity | 613 | 497 | 450 | 301 | 64 |
Total Common Equity | 554 | 467 | 408 | 252 | 32 |
Shares Outstanding | 84.80 | 60.20 | 49.30 | 40.80 | 27.10 |
Book Value Per Share | 6.54 | 7.76 | 8.28 | 6.18 | 1.17 |
Fiscal Year End for Syndax Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 578 | 374 | 406 | 438 | 484 |
Receivables | 0 | 3 | 0 | 1 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 3 | 4 | 3 | 2 | 2 |
Total Current Assets | 581 | 381 | 409 | 442 | 490 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 30 | 16 | 19 | 17 | 5 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 613 | 399 | 431 | 460 | 497 |
Liabilities & Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 10 | 6 | 11 | 8 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 40 | 32 | 18 | 15 | 24 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 7 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 58 | 39 | 30 | 24 | 29 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 59 | 40 | 31 | 24 | 30 |
Shareholders Equity | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,456 | 1,190 | 1,179 | 1,170 | 1,161 |
Retained Earnings | -902 | -830 | -779 | -734 | -693 |
Other Equity | 0 | 0 | -1 | 0 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 554 | 359 | 400 | 436 | 467 |
Total Liabilities & Shareholder's Equity | 613 | 399 | 431 | 460 | 497 |
Total Common Equity | 554 | 359 | 400 | 436 | 467 |
Shares Outstanding | 84.80 | 69.60 | 69.40 | 68.50 | 60.20 |
Book Value Per Share | 6.54 | 5.16 | 5.76 | 6.36 | 7.76 |